Minimizing Terms for Toxicity Often Used in Multiple Myeloma Trials, Study Says
November 22nd 2023A cohort study of 65 clinical trials in multiple myeloma found that toxic effects are often described with subjective terminology that may not reflect adverse event rates reported in the studies.
Read More
Study Shows Higher Infection Risk in Patients With T1D in Primary, Secondary Care
November 22nd 2023Researchers concluded there is a clinically important increase in infection risk among patients with T1D in both primary care and hospital settings, and that guidelines must be developed to reflect this risk and encourage earlier treatment.
Read More
Upadacitinib Demonstrates Efficacy in RA Treatment Regardless of Patient’s Baseline CRP Levels
November 22nd 2023In a real-world, prospective study, upadacitinib demonstrated great potential for the treatment of rheumatoid arthritis (RA) regardless of a patient’s baseline C-reactive protein (CRP) levels.
Read More
Short-Term Fine Particulate Matter Exposure Increases COPD Hospitalizations
November 22nd 2023Researchers explained that developing preventative strategies and improving air quality to reduce the concentrations of air pollutants can help to reduce the hospitalizations of patients with chronic obstructive pulmonary disease (COPD).
Read More
Bevey Miner: Why Structured Data Sharing Is Crucial in Digital Health Policy
November 22nd 2023Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions, discusses the importance of incorporating structured data into digital health policy to improve the speed and efficiency of shared information across multiple health settings.
Watch
Allegations call out restrictions on medically necessary care; CDC data highlight surge in COVID-19 deaths and hospitalizations; failure to include additional Special Supplemental Nutrition Program for Women, Infants, and Children (WIC) aid raises concerns over food access.
Read More
EMBARK Data Support Delandistrogene Moxeparvovec for DMD Across All Study End Points
November 22nd 2023Over a 52-week treatment period, the gene therapy demonstrated robust evidence for a clinically meaningful benefit, including across several prespecified functional secondary end points vs placebo.
Read More
COPD Prevalence Did Not Significantly Change Overall From 2011 to 2021, Study Says
November 21st 2023Based on Behavioral Risk Factor Surveillance System data, about 6.4% of US adults in 2011 (14.3 million people) and about 6.5% (14.2 million) had COPD in 2021, showing that COPD prevalence did not significantly change throughout the decade.
Read More
Early Changes in PROs Are Linked With Treatment Response, Survival in Gastrointestinal Cancer
November 21st 2023A cohort study found that early changes in patient-reported outcomes (PROs) were associated with treatment response and survival outcomes in patients with advanced gastrointestinal cancer, supporting the need for more routine implementation of PRO monitoring in cancer care spaces.
Read More
AAD Updates Guidelines for AD Treatment Using Phototherapy, Systemic Therapies
November 21st 2023These new atopic dermatitis (AD) treatment guidelines from the American Academy of Dermatology (AAD) update their 2014 recommendations for the management of AD with phototherapy and systemic therapies.
Read More
IQVIA Report Spotlights Shortages for Pain, Obesity, and Oncology Therapies
November 21st 2023A new report from IQVIA provides an overview of current US drug shortages, shedding light on major areas of concern, such as medications to address pain, cardiovascular conditions, obesity and diabetes, and multiple forms of cancer.
Read More
CDC Report Shows Decline in Youth Cancer Mortality, Highlights Racial and Ethnic Disparities
November 21st 2023While the overall rate of cancer death among children has declined substantially in recent decades, progress has stalled for Black and Hispanic children compared with White children since 2011.
Read More
HMO and EPO Insurance Plans More Likely to Promote Use of Biosimilars
November 21st 2023Health plan type highly influences the likelihood of biosimilar uptake, with low-flexibility insurance plans more likely to have patients who either switched to a biosimilar or were initiated on a biosimilar.
Read More
Poor 1-Month BCVA After Intravitreal Injection Was Primary Predictor of Blindness
November 20th 2023Patients with retinal vein occlusion-related macular edema had a higher likelihood of blindness and low vision if they had low best-corrected visual acuity after 1 month of intravitreal treatment.
Read More
RHC Still Recommended Over Echocardiography for Detecting COPD-PH
November 20th 2023In a single-center, retrospective analysis, echocardiography demonstrated low sensitivity but high specificity for diagnosing pulmonary hypertension (PH) in advanced chronic obstructive pulmonary disease (COPD).
Read More
Health Care Personnel Influenza Vaccination Coverage Declined After COVID-19 Pandemic, Study Says
November 20th 2023Researchers hypothesized that health care personnel (HCP) influenza vaccination coverage decreased during the pandemic because individuals may have believed that it was less important than in previous years.
Read More
What We’re Reading: Rising Flu Cases; RSV Drug Shortage; Forever Chemical Restrictions
November 20th 2023Health officials said that at least 7 states reported high levels of illness, with cases also rising in other parts of the country; a group of Senate Democrats demanded answers about the shortage of nirsevimab, a new respiratory syncytial virus (RSV) drug; Pentagon officials told Congress that eliminating per- and polyfluorinated substances would undermine military readiness.
Read More
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Read More
Biosimilar Substitution Can Reduce TCOC, Improve Provider Performance in Value-Based Payment Models
November 20th 2023A simulation study estimated the impact of biosimilar substitution on total cost of care (TCOC) and provider financial performance in the final performance period of the Oncology Care Model.
Read More
AMA Continues Call for Medicare Payment System Fix During Interim Meeting
November 20th 2023The American Medical Association (AMA) is continuing to urge Congress to stop the impending 3.4% cut to physicians, and other organizations also weigh in on the pros and cons of the 2024 Medicare Physician Fee Schedule.
Read More